Averkov, O. V. (2021). Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk. «FIRMA «SILICEA» LLC.
Chicago Style (17th ed.) CitationAverkov, O. V. Early Discontinuation of Dual Antiplatelet Therapy via Acetylsalicylic Acid Cessation in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Interventions to Reduce the Bleeding Risk. «FIRMA «SILICEA» LLC, 2021.
MLA (9th ed.) CitationAverkov, O. V. Early Discontinuation of Dual Antiplatelet Therapy via Acetylsalicylic Acid Cessation in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Interventions to Reduce the Bleeding Risk. «FIRMA «SILICEA» LLC, 2021.